| 1.53 -0.22 (-12.57%) | 10-01 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.04 |
1-year : | 3.84 |
| Resists | First : | 2.6 |
Second : | 3.28 |
| Pivot price | 2.68 |
|||
| Supports | First : | 1.5 |
Second : | 1.24 |
| MAs | MA(5) : | 2.24 |
MA(20) : | 2.74 |
| MA(100) : | 4.38 |
MA(250) : | 6.64 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 9.3 |
D(3) : | 14.4 |
| RSI | RSI(14): 21.4 |
|||
| 52-week | High : | 11.3 | Low : | 1.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CVRX ] has closed below the lower bollinger band by 15.1%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ CVRX ] is to continue within current trading range. Bollinger Bands are 1.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.79 - 1.8 | 1.8 - 1.81 |
| Low: | 1.48 - 1.49 | 1.49 - 1.5 |
| Close: | 1.51 - 1.53 | 1.53 - 1.54 |
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.
Wed, 30 Sep 2026
$CVRX stock is down 33% today. Here's what we see in our data. - Quiver Quantitative
Tue, 29 Sep 2026
CVRx, Inc. Announces Late-Breaking Data And New Clinical Evidence On Barostim At The HFSA Annual Scientific Meeting 2026 - marketscreener.com
Tue, 29 Sep 2026
New registry analyses of a heart failure device are scheduled for a late-breaking session. - Stock Titan
Tue, 29 Sep 2026
CVRx Announces Late-Breaking Data and New Clinical Evidence - GlobeNewswire
Wed, 23 Sep 2026
CVRx names John Landry as CFO - MedTech Dive
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 27 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 15.1 (%) |
| Held by Institutions | 65.8 (%) |
| Shares Short | 2,360 (K) |
| Shares Short P.Month | 1,930 (K) |
| EPS | -1.98 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.75 |
| Profit Margin | -85 % |
| Operating Margin | -83 % |
| Return on Assets (ttm) | -28.8 % |
| Return on Equity (ttm) | -133.5 % |
| Qtrly Rev. Growth | 15.6 % |
| Gross Profit (p.s.) | 1.99 |
| Sales Per Share | 2.29 |
| EBITDA (p.s.) | -1.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -40 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | -0.78 |
| PEG Ratio | 0 |
| Price to Book value | 2.03 |
| Price to Sales | 0.66 |
| Price to Cash Flow | -1.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|